We have demonstrated that multigene panel testing on FFPE tumor samples can be used to detect germline variants beyond BRCA1/2, as 10 germline variants in other ovarian cancer risk genes were identified in tumor testing (BRIP1, MSH2, RAD51C, RAD51D) (Table S2). This evidence concerns the gene BRCA1 and ovarian carcinoma.